SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Multiple Sclerosis
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
1352458508092810v1
14/8/1137    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (3)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Centonze, D
Right arrow Articles by Battistini, L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Centonze, D
Right arrow Articles by Battistini, L
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

research-article

Early relapses after the first dose of natalizumab in active multiple sclerosis patients

D Centonze

Department of Neuroscience, Neurologic Clinics, Tor Vergata University, Rome, Italy; European Center for Brain Research (CERC)/Fondazione Santa Lucia, Rome, Italy centonze{at}uniroma2.it

R Furlan

Neuroimmunology Unit, Institute of Experimental Neurology (INSpe), San Raffaele Scientific Institute, Milan, Italy

C Gasperini

Department of Neurosciences, San Camillo Hospital, Rome, Italy

M Salvetti

Neurologic Clinics, Center for Experimental Neurological Therapy, La Sapienza University, Rome, Italy

L Battistini

European Center for Brain Research (CERC)/Fondazione Santa Lucia, Rome, Italy

Background

Natalizumab is prescribed in Italy in patients who experienced at least two clinical relapses during a 12-month therapy with other approved immunomodulatory agents.

Results

In 7 of 35 patients selected on the basis of these recommendations, we have observed clinical relapses occurring within 24 h after the first dose of natalizumab.

Conclusion

The mechanism by which a first injection of natalizumab may precipitate a clinical relapse in patients with MS is unknown. We speculate that natalizumab can promote the release of inflammatory mediators from lymphocytes present in the central nervous system at the time of the first infusion, thus favoring the clinical manifestation of a pre-existing active lesion.

Key Words: monoclonal antibody • VLA-4 • tysabri

This version was published on September 1, 2008

Multiple Sclerosis, Vol. 14, No. 8, 1137-1138 (2008)
DOI: 10.1177/1352458508092810
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Mult SclerHome page
F. Rinaldi, P. Perini, M. Calabrese, L. Rinaldi, and P. Gallo
Severe relapses after the first infusion of natalizumab in active relapsing--remitting multiple sclerosis
Multiple Sclerosis, November 1, 2009; 15(11): 1359 - 1362.
[Abstract] [PDF]

Home page
 Mult SclerHome page
J Haartsen, M Marriott, and H Butzkueven
Re: Early relapses after the first dose of natalizumab in active multiple sclerosis
Multiple Sclerosis, April 1, 2009; 15(4): 520 - 520.
[PDF]


Advertisement